Shenouda, G., Diaz, R., Abdulkarim, B., Petrecca, K., Owen, S. P., Panet-Raymond, V., Mohammad, A., Barrera, M., Davalan, W., Baciu, A., Carvalho, T., Charbonneau, M., Perna, M., Kozel, T., Hall, J., Guiot, M., Souhami, L. (2025). Phase II propensity-matched controlled trial evaluating metformin as an adjunct to neo-adjuvant, concomitant, and adjuvant temozolomide and hypofractionated-accelerated radiotherapy (M-HART) in glioblastoma patients (NCT02780024).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.2064